News | May 22, 2024
AstraZeneca plans $1.5 billion ADCs manufacturing facility in Singapore
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Subscribe To Our Newsletter & Stay Updated
